u/dario_vermeulen

Have you seen the special authorization criteria for your province?

Net peptide content accounts for counterion, water and residual solvent. On some of these compounds the gap between purity and net content is substantial and entirely honest.

Agree. The GIP component is the interesting half and it barely gets discussed outside c/glp1science.

Those criteria were revised at renewal, so the version quoted upthread is out of date.

Have you asked the pharmacist to check?

the appetite effect is blunter than sema, in a good way, most weeks

Small fix: SURMOUNT is the obesity programme, SURPASS is the type-2 programme. They are different endpoints and the numbers do not transfer.

the same product can be covered in one province and not the next

2.5mg is a four-week starting dose, not a maintenance dose. Worth being precise since people search these threads.

It is a dual GIP and GLP-1 receptor agonist, and the GIP arm is the part that has no equivalent in the semaglutide threads. That is why the side-effect profile reads differently rather than just milder.

It is a dual GIP and GLP-1 receptor agonist, and the GIP arm is the part that has no equivalent in the semaglutide threads. That is why the side-effect profile reads differently rather than just milder.

regain is the expected outcome and framing it as failure helps nobody

Disagree with the conversion table. There is no validated equivalence between the two molecules and posting one as though there is does real damage.

Right, and net peptide content is where the counterion and the water go. Both numbers can be honest and very different.

Disagree — that name refers to at least two different molecules depending on who is selling it. The thread needs to be specific.

sulphur burps are the signature complaint and they are not dangerous

Went 10 to 12.5 on the calendar and had the worst fortnight of the whole run. Dropped back to 10 and everything settled.

Area percent is the peak area of your compound over the total integrated area, at one wavelength, on one gradient. It is a relative measure of what the detector saw, not a mass fraction of the vial.

nobody here can write you a taper schedule

a total of 0.4% tells you less than four named impurities adding to 0.6%

Same experience with the appetite effect being flatter across the week rather than front-loaded.

Area percent or net peptide content? They answer different questions.

coming back later is allowed and it is common

the appetite effect is blunter than sema, in a good way, most weeks

What storage conditions did they specify?

Which province?

the exception drug status route exists in several provinces

Small fix — 214nm, not 280nm. It matters here because the impurity you are asking about barely absorbs at the longer wavelength.

pens and vials are the same molecule, the price is the difference

interval stretching is the most commonly described approach here

zepbound and mounjaro are the same compound with different labels

Nothing here is medical or legal advice. The pharmacist and the prescriber are the people who can act, and both are faster than a forum.

The thing nobody warned me about was how much of this is logistics — storing it, remembering it, the same day every week.

SURMOUNT-1 ran 72 weeks with the top arm around 21% mean body weight change.

Saving this one. It is the clearest statement of the stall problem I have read here.

Push back: that is a taper schedule aimed at another member and this board does not host those.

a total of 0.4% tells you less than four named impurities adding to 0.6%

Agree. The GIP component is the interesting half and it barely gets discussed outside c/glp1science.

Kept every form and reference number. When they had no record of a submission, I did.

dual agonist, so the GIP arm is doing something the sema threads will not tell you about

Right, and the habits from the losing phase are the part that has to outlive the dose.